Clinical trial
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study
NCT06334133 is registered in ClinicalTrials.gov with vTv Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study
- Lead sponsor
- vTv Therapeutics
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 14, 2024
- Completion date
- May 31, 2027
- Enrollment
- 150 (estimated)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.